Compounds > gemcabene
Page last updated: 2024-11-07

gemcabene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID157692
CHEMBL ID2110686
SCHEMBL ID761631
MeSH IDM0287619

Synonyms (30)

Synonym
gemcabene
unii-b96ux1ddks
gemcabene [inn]
pd72953
pd 72953
b96ux1ddks ,
6,6'-oxybis(2,2-dimethylhexanoic acid)
pd-72953
183293-82-5
2,2,2',2'-tetramethyl-6,6'-oxydihexanoic acid
hexanoic acid, 6,6'-oxybis 2,2-dimethyl-
DB05123
6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethyl-hexanoic acid
SDMBRCRVFFHJKR-UHFFFAOYSA-N
SCHEMBL761631
CHEMBL2110686
DTXSID60171407
6-(5-carboxy-5-methylhexoxy)-2,2-dimethyl-hexanoic acid
6,6'-oxybis(2,2-dimethylhexanoic) acid
FT-0743032
Q27095571
HY-109567
pd72953; pd 72953; pd-72953
BCP34011
CS-0031888
MS-24364
hexanoic acid, 6,6'-oxybis[2,2-dimethyl-
6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid
AC-35730
AKOS040733245

Research Excerpts

Overview

Gemcabene is a novel lipid-lowering agent with a mechanism of action independent of the LDLR. It has previously demonstrated the ability to reduce levels of LDL-C on top of maximally tolerated statins.

ExcerptReferenceRelevance
"Gemcabene is a novel lipid-lowering agent with a mechanism of action independent of the LDLR, which has previously demonstrated the ability to reduce levels of LDL-C on top of maximally tolerated statins."( Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
Bakker-Arkema, R; Bisgaier, C; Durst, R; Gaudet, D; Golden, L; Hegele, RA; Kastelein, JJ; Lepor, N; Masson, L; Stein, E, 2019)		1.6

Toxicity

ExcerptReferenceRelevance
" However, the number of effective and safe oral agents for patients not at LDL-C goal is limited."( Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients.
Bakker-Arkema, R; Bays, H; Bisgaier, C; Koren, M; Stein, E, )		0.44

Compound-Compound Interactions

ExcerptReferenceRelevance
" This observation revealed a possible transporter-mediated drug-drug interaction (DDI) between gemcabene and quinapril."( Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril.
Bond, BR; Chupka, J; Feng, B; Heath, TG; Yu, Y; Yuan, H; Zheng, JY, 2009)		0.8

Dosage Studied

This study evaluated the efficacy and tolerability of gemcabene, a new lipid-altering agent, in a double-blind, randomized, dose-response study of 161 patients with high-density lipoprotein (HDL) cholesterol of <35 mg/dl. High plasma concentrations of gemCabene achieved in humans and rats upon oral dosing corroborate with gemcabe inhibition of renal OAT3-mediated secretion of quinaprilat in vitro.

ExcerptRelevanceReference
"This study evaluated the efficacy and tolerability of gemcabene, a new lipid-altering agent, in a double-blind, randomized, dose-response study of 161 patients with high-density lipoprotein (HDL) cholesterol of <35 mg/dl and serum triglyceride (TG) levels of either >/=200 (n = 94) or <200 mg/dl (n = 67)."( Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
Bays, HE; Dujovne, CA; MacDougall, DE; McKenney, JM; Nyberg, J; Schrott, HG; Zema, MJ, 2003)		0.81
" Dose-response models were developed for the lipid effects (low-density lipoprotein cholesterol [LDL-C] and high-density lipoprotein cholesterol); adverse effects, such as persistent alanine aminotransferase elevation and myalgia; tolerability issues, such as headache; and risk reduction for coronary artery disease-related events for 5 statins, ezetimibe, gemcabene, and their combinations."( Model-based development of gemcabene, a new lipid-altering agent.
Bakker-Arkema, R; Hartman, D; Hermann, D; Mandema, JW; Milad, M; Sheiner, T; Wang, W, 2005)		0.8
" High plasma concentrations of gemcabene (>100 microM) achieved in humans and rats upon oral dosing corroborate with gemcabene inhibition of renal OAT3-mediated secretion of quinaprilat in vitro."( Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril.
Bond, BR; Chupka, J; Feng, B; Heath, TG; Yu, Y; Yuan, H; Zheng, JY, 2009)		0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (17.65)18.2507
2000's5 (29.41)29.6817
2010's8 (47.06)24.3611
2020's1 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.38 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index27.81 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (16.67%)5.53%
Reviews4 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (61.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		3.1310amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		3.1310gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
gemfibrozil
[no description available]		1.9910aromatic etherantilipemic drug
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		3.110benzenes;
phenyl acetates
8-bromo cyclic adenosine monophosphate
8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.		2.08103',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.0210azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
quinapril
Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.		7.0510dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
8-chloro-cyclic adenosine monophosphate
[no description available]		2.0810
pd 142505-0028
[no description available]		3.1310
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.0810secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
ezetimibe
Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).		4.9221azetidines;
beta-lactam;
organofluorine compound		anticholesteremic drug;
antilipemic drug;
antimetabolite
avasimibe
[no description available]		3.110monoterpenoid
bms201038
BMS201038: an anticholesteremic agent and microsomal triglycide transfer protein inhibitor. lomitapide : A member of the class of benzamides obtained by formal condensation of the carboxy group of 4'-(trifluoromethyl)biphenyl-2-carboxylic acid with the primary amino group of 9-[4-(4-aminopiperidin-1-yl)butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide. Used (as its mesylate salt) as a complement to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia.		3.6920(trifluoromethyl)benzenes;
benzamides;
fluorenes;
piperidines		anticholesteremic drug;
MTP inhibitor
etc-1002
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid: inhibits ATP citrate lyase (ACL); has anti-atherosclerotic activity. bempedoic acid : An alpha,omega-dicarboxylic acid that is pentadecanedioic acid which is substituted by methyl groups groups at positions 2 and 14, and by a hydroxy group at position 8. It is a drug used for the treatment of high LDL cholesterol, which is sometimes referred to as 'bad cholesterol'.		3.6920alpha,omega-dicarboxylic acidantilipemic drug;
EC 2.3.3.8 (ATP citrate synthase) inhibitor;
prodrug
glucagon
Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.		2.0810peptide hormone
oligonucleotides
[no description available]		3.6920
3'-azido-3'-deoxy-5'-o-beta-glucopyranuronosylthymidine
3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine: major metabolite of zidovudine		2.0210pyrimidine 2',3'-dideoxyribonucleoside
ConditionIndicatedRelationship StrengthStudiesTrials
Metastase
[description not available]		02.610
Experimental Neoplasms
[description not available]		02.610
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.610
Apolipoprotein B-100, Familial Defective
[description not available]		05.8121
Hyperlipoproteinemia Type II
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).		05.8121
Hyperlipemia
[description not available]		02.1710
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		02.1710
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.1710
Disease Exacerbation
[description not available]		02.1710
Fatty Liver, Nonalcoholic
[description not available]		02.1710
Alloxan Diabetes
[description not available]		02.1710
Hepatocellular Carcinoma
[description not available]		02.1710
Innate Inflammatory Response
[description not available]		02.1710
Cirrhosis, Liver
[description not available]		02.1710
Cancer of Liver
[description not available]		02.1710
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1710
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.1710
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1710
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		14.1710
Dyslipidemia
[description not available]		02.2110
Hypertriglyceridemia
A condition of elevated levels of TRIGLYCERIDES in the blood.		04.7721
Dyslipidemias
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.		02.2110
Cancer of Pancreas
[description not available]		02.0810
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.0810
Elevated Cholesterol
[description not available]		06.431
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		18.431
Apoplexy
[description not available]		02.9510
Postherpetic Neuralgia
[description not available]		02.9510
Acute Confusional Senile Dementia
[description not available]		02.9510
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.9510
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		02.9510
Neuralgia, Postherpetic
Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.		02.9510
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210